Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate

Targeting caspase-4/5 has the potential to address a broad range of inflammatory conditions, including inflammatory bowel disease, hidradenitis suppurativa, severe asthma, and chronic obstructive pulmonary disease VENT-04 is the seventh development candidate created using Ventus’ proprietary ReSOLVE® platform WALTHAM, Mass. & MONTREAL — January 7, 2026 — (BUSINESS WIRE) — Ventus Therapeutics, a clinical-stage biopharmaceutical […] The post Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate appeared first